Amgen Anakinra Arthritis Advisory Committee Review Expected In August
Executive Summary
Amgen expects an advisory committee review of its rheumatoid arthritis treatment anakinra in August.
You may also be interested in...
Amgen/Praecis Ask For FDA Meeting After Plenaxis Deemed "Not Approvable"
Amgen and Praecis are requesting a meeting with FDA to discuss issues surrounding the NDA for their prostate cancer treatment Plenaxis (abarelix).
Amgen/Praecis Ask For FDA Meeting After Plenaxis Deemed "Not Approvable"
Amgen and Praecis are requesting a meeting with FDA to discuss issues surrounding the NDA for their prostate cancer treatment Plenaxis (abarelix).
Amgen IL-1ra Sepsis Data May Help Support Arthritis Launch, Firm Says
Amgen's extensive database for interleukin-1 receptor antagonist in sepsis patients may help the company position the product as a safer alternative to the TNF inhibitor Enbrel in the rheumatoid arthritis market, Amgen Senior VP-Sales & Marketing Stan Benson suggested during a Nov. 8 analysts meeting in New York City.